Anti-EGFR (Panitumumab), Humanized Antibody

ALTERNATE NAMES:	ERBB, ERRP, HER1, mENA, ERBB1, PIG61, NISBD2, EGFR	
CATALOG NO. :	A1050-100	
AMOUNT:	100 µg	
IMMUNOGEN:	EGFR	
HOST/ISOTYPE:	Recombinant/ Human IgG2k	
SOURCE:	CHO cells	
CLONALITY:	Monoclonal	
FORM:	Liquid	
FORMULATION:	In PBS, pH 7.5	
PURIFICATION:	Protein A purified	
SPECIES REACTIVITY:	Human	
STORAGE CONDITIONS:	For long term storage, store at -20°C in small aliquots to prevent freeze-thaw cycles.	

RELATED PRODUCTS:

- Anti-VEGF (Bevacizumab), humanized Antibody (Cat. No. A1045-100)
- Anti-HER2 (Trastuzumab), humanized Antibody (Cat. No. A1046-100)
- Anti-EGFR (Cetuximab), Chimeric Antibody (Cat. No. A1047-100)
- Anti-TNF-α (Adalimumab), humanized Antibody (Cat. No. A1048-100)
- Anti-CD20 (Rituximab), Chimeric Antibody (Cat. No. A1049-100)
- Human CellExp™ ErbB2 / HER2 / CD340, human recombinant (Cat. No. 7397-10)
- HER2, Active, Human Recombinant (Cat. No. 8011-5)
- HER2, Active (Cat. No. 7762-5)
- HER2/ErbB2 Antibody (Cat. No. 3783-100)

FOR RESEARCH USE ONLY! Not to be used on humans.

DESCRIPTION: Panitumumab is the human monoclonal antibody against epidermal growth factor receptor (EGFR). The EGFR is a member of a subfamily of type I receptor tyrosine kinases, including EGFR (HERI, c-ErbB-l), HER2/neu, HER3, and HER4. EGFR is a transmembrane glycoprotein that is constitutively expressed in many normal epithelial tissues, including the skin and hair follicle. Overexpression of EGFR is also detected in many human cancers, including those of the colon and rectum. Panitumumab binds specifically and selectively to the EGFR, preventing binding of activating ligands, such as the EGF and transforming growth factor-α. This binding results in blockade of the essential downstream signaling pathways that are known to govern apoptosis, proliferation and differentiation of both normal and neoplastic cell types in a wide array of tissues.

Note: This information is only intended as a guide. The optimal dilutions must be determined by the user.